

INTERVENTIONAL STUDIES				
Short Title	Sponsor	PI	Target	Recruited
Arimoclomol in IBM (phase II/III)	Orphazyme	P. Machado	50	34
Sideros - Idebenone in DMD (phase III)	Santhera	R. Quinlivan	5	7
SPIMM-301 (phase III)	Stealth	R. Pitceathly	9	11
Ankle Foot Orthoses on Postural Stability in people with Inherited Neuropathies	St George's University	G. Ramdharry	15	11
Goal setting to Increase Physical activity in Myotonic Dystrophy & Channelopathies	UCLH	S. Holmes	88	25
COMMEND Acceptance and Commitment Therapy	UCL	R. Orrell	3	3
Modifying Immune Response and OutComes in ALS (MIROCALS)	Centre Hospitalier Universitaire de Nimes	N. Sharma	14	6
Sideros Idebenone in DMD Open Label Ext (phase III)	Santhera	R. Quinlivan	6	7
Arimoclomol in ALS (phase III)	Orphazyme	M. Hanna	10	4
REN001 in PMM (open label, phase Ib)	Reneo Pharma	R. Pitceathly	12	3
INTERVENTIONAL STUDIES IN SET UP				
OPTIC - Optimal Induction Treatment in CIDP (IVIG/IVMP vs IVIG/placebo) (phase IV)	University of Amsterdam	M. Lunn	NHNN 10 UK 40 Global 96	
2 DG in Mitochondrial Disease	(Non-CTIMP Interventional)	R. Pitceathly	10	
UCB7665/Placebo in Subjects with CIDP (phase IIa)	UCB	M. Lunn	2	
BIIB078 in Adult with C9ORF72-associated ALS	Biogen	V.Libri/M.Hanna	5	
REN001-103 in McArdle disease (open label, phase Ib)	Reneo Pharma	R. Quinlivan	12	